UOC
CABA icon

UBS O'Connor’s Cabaletta Bio CABA Stock Holding History

UBS O'Connor’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-48,332
Closed -$736K – 524
2023
Q3 		$736K Sell
48,332
-33,000
-41% -$451K 0.01% 362
2023
Q2 		$1.05M Buy
81,332
+36,332
+81% +$394K 0.02% 377
2023
Q1 		$372K Buy
+45,000
New +$421K 0.01% 486

Other funds holding CABA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

UBS O'Connor's CABA Position: Q4 2023 in Review

UBS O'Connor sold out of Cabaletta Bio (CABA) in Q4 2023, closing a stake of 48,332 shares — an estimated $736K sold.

UBS O'Connor first reported a position in CABA in Q1 2023 and held it in 3 quarters. The position peaked at $1.05M in Q2 2023. 128 funds tracked by Wall St. Rank hold CABA as of Q4 2023.

  • UBS O'Connor reported no remaining Cabaletta Bio position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 48,332 Cabaletta Bio shares in Q4 2023, an estimated $736K.
  • UBS O'Connor first reported a position in Cabaletta Bio in Q1 2023 and held it in 3 quarters.
  • UBS O'Connor's Cabaletta Bio position peaked at $1.05M in Q2 2023.
  • 128 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.